Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic InFuse payment docked

This article was originally published in The Gray Sheet

Executive Summary

Maximum add-on payment halved to $4,450 upon firm's notification that a single-level fusion requires only one product per procedure. CMS mistakenly believed two InFuse devices were needed, the agency explains in an 1Oct. 6 hospital inpatient prospective payment system correction notice. Medtronic is the first device firm to qualify for the new-tech provision (2"The Gray Sheet" Aug. 4, 2003, p. 6)...

You may also be interested in...



First Device Qualifies For Add-On Payment; CMS Retains Proposed Threshold

The device industry's hopes to reduce the Centers for Medicare & Medicaid Services' new technology "add-on" payment threshold are riding on a provision in the House's "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1)

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel